Insmed CEO William Lewis Has Sold $96M in Career INSM Stock — CMO Flammer at $74M Career

Five Insmed insiders sold a combined $11.51 million in INSM stock, with CEO William Lewis and Chief Medical Officer Martina Flammer each selling approximately $4.7 million. What makes Insmed's insider selling remarkable is the cumulative career context — the CEO has sold $96.1 million, the CMO $74 million, and the CFO $43.1 million.

Five Insiders, Deep Career Selling

Insider	Title	Recent Transactions	Recent Value	Career Sales	Shares After
William Lewis	Chairman & CEO	14	$4.69M	$96.1M	303,911
Martina Flammer, M.D.	Chief Medical Officer	10	$4.72M	$74.0M	83,111
Sara Bonstein	Chief Financial Officer	3	$0.81M	$43.1M	80,506
Roger Adsett	Chief Operating Officer	3	$0.75M	$15.2M	107,601
Michael Smith	Chief Legal Officer	3	$0.55M	$24.7M	57,037
Total: 5 insiders, 33 transactions			$11.51M	$253.1M

$253 Million in Combined Career Sales

The aggregate career total is the real story: these five insiders have sold a combined $253.1 million in Insmed stock. For a biotech company with a ~$12 billion market cap, that represents substantial founder and executive monetization.

CEO Lewis: $96.1M Career — Nearly $100M

William Lewis is approaching the $100 million career selling milestone. His 14 transactions in this round yielded $4.69M, and he retains 303,911 shares (~$21M). The CEO has now sold roughly 4.6x the value of his remaining position — a significant tilt toward cash over equity.

CMO Flammer: $74M — The Doctor Who Sells

CMO Martina Flammer's $74 million in career sales is exceptional for a Chief Medical Officer. She oversees Insmed's clinical programs, including the company's key drug Arikayce for lung infections. Her 10 transactions for $4.72M leave her with 83,111 shares (~$5.8M) — meaning she's sold roughly 13x her current position value over her career.

CFO Bonstein: $43.1M — Quiet Giant

CFO Sara Bonstein has sold $43.1 million in career INSM stock — a remarkable total for a finance chief. Her $810K sale in this round is modest relative to her history. She retains 80,506 shares (~$5.6M), meaning she's sold 7.7x her remaining position.

The Biotech Monetization Machine

Insmed develops treatments for serious lung diseases, with Arikayce (amikacin liposome inhalation suspension) as its commercial product and brensocatib as a promising pipeline candidate. The company's market cap of ~$12 billion reflects investor optimism about its drug pipeline.

But the insider selling tells another story:

• CEO: $96.1M career — approaching nine figures in sales
• CMO: $74.0M career — the person who runs clinical trials has sold $74M
• CFO: $43.1M career — the finance chief has monetized aggressively
• CLO: $24.7M career — even the legal officer has sold nearly $25M
• COO: $15.2M career — every C-suite member selling in the millions

For INSM investors, the $253M in combined career sales from five insiders is a clear signal that the leadership team has been consistently taking money off the table through Insmed's appreciation. The question isn't whether the science is real — it's whether the insiders' $253M in monetized gains already reflects the best-case scenario for the company's drugs.